Lake Street Capital Markets Starts PAVmed (PAVM) at Buy
- S&P 500, Nasdaq hit new peaks after May inflation data misses estimates
- Nike (NKE) Surges 13% After Beating Q4 Sales, Analysts Raise PTs After 'Exceptional' Quarter
- Banks clear Fed stress test; paving way to boost buybacks, dividends
- FedEx (FDX) Tops Q4 EPS by 2c, Offers FY22 Guidance
- Didi IPO Pricing: Seeking to Raise $4 Billion at Valuation of $62 Billion to $67 Billion, Books Already Fully Covered on First Day
Lake Street Capital Markets initiates coverage on PAVmed (NASDAQ: PAVM) with a Buy rating and a price target of $5.00.
Shares of PAVmed closed at $2.00 yesterday.
You May Also Be Interested In
- UPDATE: Redburn Starts AT&T (T) at Sell
- UPDATE: Stephens Starts Enphase Energy (ENPH) at Overweight, 'Leading Microinverter Company'
- UPDATE: Credit Suisse Starts Desktop Metal Inc. (DM) at Neutral
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!